
News|Articles|October 12, 2012
Intranasal fentanyl spray benefits compared with oral agents for breakthrough cancer pain
Patients with breakthrough cancer pain (BTCP) may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online for The Annals of Pharmacotherapy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
4 things to know about the Abarca/LucyRx merger
2
Healthcare's AI push is creating a new workforce challenge
3
EHR-based risk calculator reduces 3-year diabetes risk in patients with prediabetes
4
FDA expands Capvaxive indication to include adolescent patients at risk for pneumococcal disease
5

































